Munich Medical Service offers its patients a full range of urological diagnostics in the leading clinics of Munich

Thanks to the synergetic use in clinical practice of both traditional medicine methods and completely new ones, innovative developments, Munich clinics are widely known not only among patients and doctors in Germany, but also abroad. The combined approach to diagnostics and therapy of various diseases guarantees our patients the highest quality examination and effective treatment.

All specialists offered by our company are doctors of the highest category, who carry out complete diagnostics and treatment of the whole range of diseases of the urogenital tract

During the examination we use the latest technical equipment, for example:

Sonoline S2000 differing from traditional devices by several innovative methods. These include a technology called dynamic tissue contrasting (TCETM), which enables imaging by increasing tissue differentiation (by highlighting tissue edges and reducing image noise).

Mindray M5 with Smart 3D technology

Urologic preventive examination includes the following elements:

• Consultation
• History taking
• Clinical examination
• Transrectal ultrasonography (TRUS)
• Laboratory blood tests, including hormonal panel, PSA levels and the latest prostate and bladder cancer markers
• Ultrasound of kidneys and adrenal glands
• Bladder ultrasound
• Scrotum ultrasound
• Trasrectal 3D ultrasound of the prostate gland
• Urethrocystoscopy
• Urogram
• Written epicrisis

If necessary, the most modern diagnostic methods are used:

• High-field magnetic resonance imaging (3 T MRI) 
• Magnetic Resonance Spectroscopy (MRS)
• CEUS contrast-enhanced ultrasound examinations
• Parametric MRI
• Fusion prostate biopsy
• PET-CT with radioactive choline
• PSMA PET-CT is the latest diagnostic test for recurrence of prostate cancer.

German medicine relies on safe and non-invasive cancer detection. There is a number of tests,t o a high degree of accuracy allowing to identify high-risk patients and to use invasive tests to confirm the diagnosis only in this group.

For example, laboratory blood tests include state-of-the-art biomarkers used to diagnose prostate cancer. These include the PCA3-мRNA Score - a molecular genetic test that has exceptional specificity for prostate cancer for timely and accurate detection of carcinoma. The higher the PCA3 value, the more likely it is that the tumor is larger than critical. A low PCA3 value indicates a minimal risk of having prostate cancer. The assay is performed by drawing and processing blood.

PCa-3 is a genetic cancer-specific marker, a prostate-specific gene located on chromosome 9. In cases of prostate carcinoma, there is a 60- to 100-fold increase in its expression in 95% of cases. For the fidelity of value calculations in each case, the ratio of PCa-3 mРНК to PCA-mРНК is calculated. If the obtained ratio exceeds 35, the probability of prostate carcinoma increases and a biopsy is recommended to verify the diagnosis.

PCa-3 levels do not correlate with prostate size, but with tumor volume and degree of malignancy. At the moment, research is underway that will make it possible in the future to make a prognosis of the course of the disease based on this indicator.

Another cancer-specific marker that allows non-invasive detection of bladder cancer is UBC, a specific bladder cancer antigen, the level of which is determined in the urine.

The newest development in ultrasound examination of the prostate is elastography, which allows to determine tumor foci, their boundaries and depth of occurrence, as well as to make a tentative differentiation of benignity of the process.

For histological diagnosis of prostate cancer the prostate biopsy under local anesthesia or sedation (modern anesthesia technique) can be offered. Sampling is performed transrectally, i.e. through the rectum under ultrasound control.

On the basis of preventive examination and diagnostic tests, specialists propose a conservative or operative treatment strategy.